Latest Intelligence on Cardiovascular and Diabetes in United Kingdom

Published within

« | 1 | 2 | 3 | 4 | » »|

Type Product title / description Pub Price
Expert View
Expert View

Johnson & Johnson: can canagliflozin do what dapa didn't?

New clinical trial data for canagliflozin have revealed that its blood glucose-lowering abilities show superiority to blockbuster gold-standard Januvia, with the added benefit of weight loss. The potential for first-to-market SGLT-2 inhibitor status in the US and its good safety and efficacy profile boost canagliflozin's chances for success in a crowded diabetes market.

Published By Datamonitor
14 Jun 2012
CommentWire
CommentWire

GlaxoSmithKline: Avandia's future questioned following US report

GlaxoSmithKline is back in the hot seat following the release of a US Senate report that highlights serious health risks associated with its diabetes drug Avandia. The report also criticizes the company for its handling of safety data and although GSK has rejected these claims and issued a fierce defense of its drug, the FDA is now under pressure to order the market withdrawal of Avandia.

Published By Datamonitor
01 Mar 2010
Expert View
Expert View

Functional food manufacturers looking to heart health

Despite numerous warnings about the risks posed by cardiovascular diseases, Brits are still not doing enough to improve their heart health. While functional food manufacturers are attempting to reverse this trend by launching products that tout heart health benefits, given the economic climate they will have to work hard to convince consumers that these products are worth the money.

Published By Datamonitor
02 Jul 2009
CommentWire
CommentWire

GlaxoSmithKline: cardio specialist to fill Avandia void

Privately-owned specialty pharma company Reliant Pharmaceuticals holds the US license to Lovaza, a dyslipidemia therapy which is thought to have provided the primary motivation for GlaxoSmithKline's $1.65 billion takeover offer. The deal will help GSK to recover sales following a loss of revenue from its diabetes drug Avandia, which has been associated with an increased risk of heart attack.

Published By Datamonitor
23 Nov 2007
CommentWire
CommentWire

AstraZeneca: further setbacks ARISE

The failure of cardiovascular treatment AGI-1067 marks the latest in a string of disappointments for AstraZeneca. While its financial investment in the high risk, high reward project has been only limited, sentiment is likely to be hit harder. The loss further pressurizes AstraZeneca to bolster its weak late-stage pipeline.

Published By Datamonitor
21 Mar 2007
CommentWire
CommentWire

Hypertension: beta-blockers to be moved to the back shelves

In its eagerly-awaited updated hypertension guidelines, the UK's National Institute for Health and Clinical Excellence has recommended against the use of beta-blockers as a first-line therapy. While the updated guidelines are good news for those drugs now given the regulator's backing in this setting, they will ensure a steady decrease in the usage of beta-blockers in hypertension in the UK.

Published By Datamonitor
28 Jun 2006
CommentWire
CommentWire

UK cardiovascular disease: statins for all?

Researchers have suggested that in order to tackle heart disease in the country, nearly all middle-aged UK men should receive statins as preventative medicine. This claim points to the great need for new guidelines concerning statin use. However, new guidelines alone might not be enough to combat the prevalence and high cost of cardiovascular disease as more effective measures are required.

Published By Datamonitor
26 May 2006
Expert View
Expert View

AstraZeneca on the acquisition trail

UK drug manufacturer AstraZeneca ended 2005 on a high note, making four significant acquisitions in December. This spending spree comprised the acquisition of product rights for one phase III drug and two phase II products, alongside the purchase of UK-based biotech firm KuDOS Pharmaceuticals. With these purchases, AstraZeneca aims to bolster its pipeline in both the short and long term.

Published By Datamonitor
04 Jan 2006
CommentWire
CommentWire

GlaxoSmithKline: a hearty triumph for Arixtra

GlaxoSmithKline looks set to enhance its thrombosis market position after study results suggested Arixtra could become the treatment of choice in acute coronary syndrome. In the study Arixtra demonstrated equivalent efficacy to Sanofi-Aventis' Lovenox but with significantly less bleeding. These results are a clear fillip for GSK, from which a considerable marketing push for Arixtra is expected.

Published By Datamonitor
07 Sep 2005
Expert View
Expert View

Pfizer's Celebrex may increase cardiovascular risk

Pfizer has announced that one of two long term cancer studies, Adenoma Prevention with Celecoxib (APC), has shown that patients receiving 400mg and 800mg of Celebrex (celecoxib) have a 2.5 fold increased risk of cardiovascular events compared to placebo. However, a similar trial, Prevention of Spontaneous Adenomatopus (PreSAP) revealed no greater cardiovascular risk than placebo.

Published By Datamonitor
20 Dec 2004

« | 1 | 2 | 3 | 4 | » »|

No help is available.